David Friedman is a Vice President with coverage of small and mid-cap biotechnology stocks. He joined Morgan Stanley in 2006 to work as an associate on the biotechnology team. Friedman left Morgan Stanley to join a hedge fund in 2009, and returned in mid-2010 to launch coverage of his current industry. Prior to joining Morgan Stanley, he was training in a general surgery residency at the Massachusetts General Hospital in Boston. David received his M.B.A. from the Harvard Business School, where he graduated with Distinction; his M.D. from the University of Pittsburgh, where he graduated Cum Laude; and his B.S. in biology from Duke University, where he graduated Cum Laude with Distinction.